Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
CPET and Exercise Prescription for Cardiac Rehabilitation
Author(s): Kaoutar Kabbadj , Nora Taiek , Wiame El Hjouji , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions
Exploring Exercise-induced Long QT
Author(s): William Wiradinata , Anita Dominique Subali , Muhammad Reva Aditya Added: 6 months ago

Electrophysiology & Arrhythmia

Inherited and Congenital Cardiac Conditions
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Heart Failure

Prevention & Chronic Conditions
End-expiratory Versus Averaged Pulmonary Artery Wedge Pressure Measurements for the Diagnosis of Exercise-induced HFpEF
Author(s): Oliver Mithoefer , Jacob Read , Carson Keck , et al Added: 2 years ago

Heart Failure
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 6 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery
Decision-making in the Cardiac ICU
Author(s): Sarah Godfrey , Alexis Barnes , Jing Gao , et al Added: 1 year ago

Vascular Disease and Surgery

Heart Failure
Cardio-obstetrics in the CICU: An Introductory Guide
Author(s): Jenna Skowronski , Eleanor Christenson , Kayle Shapero , et al Added: 11 months ago

CV Disease in Special Populations

Heart Failure
AHA 23: SUPER LIPID
Author(s): Alexander Fanaroff Added: 2 years ago
AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease… View more

Prevention & Chronic Conditions
New ESC Guidelines for the Management of Hypertension
Author(s): Rhian Touyz Added: 1 year ago
ESC Congress 2024 — Dr Rhian Touyz (McGill University Health Center, CA) joins us to discuss key highlights from the ESC 2024 guidelines for the management of elevated blood pressure and hypertension.The new guidelines introduce a new systolic blood pressure treatment target range of 120-129 mmHg, placing emphasis on an intensive target treatment as the first step in patient management - only… View more

Prevention & Chronic Conditions
Delayed ATTR-CM Diagnosis Common in HF Patients
Added: 3 weeks ago Source:  Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data… View more

Heart Failure